Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Current Liabilities
All obligations due within one year.
Zura Bio LimitedNASDAQ: ZURA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 44.3% from a year ago
Total current liabilities stood at $11.75M at the end of Q1 FY2026, down 44.3% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Total current liabilities amounted to 5.1% of total assets at the end of Q1 FY2026, down 7.1 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -44.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 12.41M USD
- Year-over-year change
- -36.4%
- 4-year CAGR
- +159.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.41M | -36.4% |
| FY2024 | 2024-12-31 | 19.51M | -3.9% |
| FY2023 | 2023-12-31 | 20.3M | +37.0% |
| FY2022 | 2022-12-31 | 14.82M | +5342.0% |
| FY2021 | 2022-03-31 | 272.29K | — |
Total Current Liabilities vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total current liabilities of $11.75M is the 8th highest of the 11 companies compared; the peer median is $25.58M.
- Its year-over-year change of -44.3% is the lowest of 11, against a peer median of +1.7%.
- Total current liabilities amounts to 5.1% of total assets for ZURA, versus a peer median of 13.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.97B | +97278.1% | +7.7% | 2.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $46.44M | +1.1% | +17.6% | 14.8% | |
| Mar 2026 | $35M | -24.9% | +44.1% | 14.9% | |
| Mar 2026 | $34.37M | -30.4% | -34.1% | 14.0% | |
| Mar 2026 | $16.78M | +18.6% | -14.0% | 12.4% | |
| Mar 2026 | $16.53M | +14.6% | -12.6% | 25.7% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -5.7% | 5.1% |
| Mar 2026 | $11.6M | +94.2% | +160.7% | 11.8% | |
| Mar 2026 | $8.34M | +2.3% | +5.4% | 4.7% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -1.1% | 4.9% |
| Peer median (excluding ZURA) | $25.58M | +1.7% | +4.0% | 13.2% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.